Lilly Cymbalta Approval Timeline In Doubt After Delay In Second NDA
Executive Summary
Lilly's plans to launch Cymbalta at the start of 2004 appear to hinge on the company's ability to convince FDA that the drug interaction issues delaying approval of duloxetine for incontinence should not hold up availability of the drug for depression
You may also be interested in...
Yentreve Goes Back To Drawing Board After Lilly/BI Withdraw NDA
Lilly and Boehringer Ingelheim's decision to withdraw the Yentreve application based upon FDA's expected negative review decision will give the companies additional time to develop a marketing strategy
Yentreve Goes Back To Drawing Board After Lilly/BI Withdraw NDA
Lilly and Boehringer Ingelheim's decision to withdraw the Yentreve application based upon FDA's expected negative review decision will give the companies additional time to develop a marketing strategy
Lilly Cymbalta Diabetic Pain Launch To Piggyback On Depression Roll-Out
Lilly's launch of two Cymbalta indications will highlight the utility of duloxetine in treating both emotional distress and physical pain